| Website | versartis.com |
| Category | BioTech |
| Employees | |
| Founded | 12/08 |
| Description | Therapeutics Protein Developer |
| TOTAL | $57M |
| FUNDING TOTAL | $57M |
| Series A, 6/09 Index Ventures | $11M |
| Series B, 2/11 New Leaf Venture Partners Advent Venture Partners Index Ventures | $21M |
| Series C, 1/13 Aisling Capital Index Ventures New Leaf Venture Partners Advent Venture Partners | $25M |
Versartis, Inc. is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders.
The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger and Joshua Silverman. Versartis is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix.
Versartis is headquartered in Redwood City, California, USA. Our lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner.
